drugset / Trial / NCT06769568

Reduced-dose Conditioning Regimen Containing TBI in HSCT Treating Elderly Patients With Aplastic Anemia

NCT06769568

Phase 2 Not yet recruiting 20 enrolled Institute of Hematology & Blood Diseases Hospital, China
NaSingle-groupOpen-labelTreatment

Summary

The TBI-containing reduced-dose conditioning regimen was used to treat elderly patients with aplastic anemia who received hematopoietic stem cell transplantation. The overall survival rate, GVHD-free survival rate, all-cause mortality,et al were studied. The modified conditioning regimen included TBI 2Gy, -7d, busulfan 3.2mg / kg-6d ; fludarabine 30mg / m2 / d-5 \~ -1d ; cyclophosphamide 25-30mg / kg / d-5 \~ -2d ; ATG ( rabbit ) 2 mg / kg / d-5 \~ -1d.

Timeline

Start
2025-01-31
Primary completion
2028-09-30
Completion
2028-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Busulfan Small molecule 3.2 mg/kg
Subject Cyclophosphamide Other / unclassified 25 mg/kg
Subject Cyclophosphamide Other / unclassified 30 mg/kg
Subject Fludarabine Small molecule 30 mg/m2
Subject Thymoglobulin Protein / enzyme biologic 2 mg/kg